What you should know:
1. The companies are suing Sandoz, alleging patent infringement on 14 patents by Sandoz’s recent abbreviated new drug application for Xifaxan.
2. Bausch holds the patents to Xifaxan, and will “continue to vigorously defend its intellectual property,” the company wrote in a statement. Xifaxan is protected by 22 patents.
3. Bausch previously defended Xifaxan in an intellectual property litigation lawsuit against Actavis Laboratories. The two companies came to an agreement, where Bausch granted Actavis a nonexclusive distribution license effective Jan. 1, 2028.
Note: A representative of Novartis was unavailable before press time. This story will be updated if we hear back.
More articles on surgery centers:
Tower Health facilities join Humana Medicare network — 3 details
Blue Cross, Cambia call off partnership days after Dr. Patrick Conway’s resignation
3 updates affecting ASC payment, collections
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.